<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04116242</url>
  </required_header>
  <id_info>
    <org_study_id>EKSG 15/074; me19Bernsmeier2</org_study_id>
    <nct_id>NCT04116242</nct_id>
  </id_info>
  <brief_title>MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease</brief_title>
  <official_title>MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate MER receptor tyrosine kinase (MERTK) signalling cascade on
      monocytes and tissue macrophages in respect to innate immune function of the cells in
      patients with cirrhosis at different stages of disease (Child A, B, C, acute decompensation,
      acute-on-chronic liver failure (ACLF)) and in comparison to patients with acute liver failure
      and to healthy controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MER receptor tyrosine kinase (MERTK) signalling cascade becomes activated on
      monocytes/macrophages during disease progression of liver cirrhosis from Child Pugh A to B/C,
      corresponding to early stages of decompensation, and before the receptor expression is
      increased. Factors involved in activation of the MERTK signalling cascade might be microbial
      products such as bacterial deoxyribonucleic acid (DNA) and other toll-like receptor
      (TLR)-ligands, MERTK ligands and cytokines, as shown elevated in cirrhotic patients.

      Given the observation that MERTK levels peak on the day of admission with organ failure and
      decrease in patients surviving the episode of acute-on-chronic liver failure (ACLF), MERTK
      Inhibition at a time during progression of cirrhosis but before manifestation of acute
      decompensation with no cirrhosis (AD) or ACLF might prevent infectious complications,
      decompensation and improve survival in patients with cirrhosis.

      This study is to investigate MER receptor tyrosine kinase (MERTK) signalling cascade on
      monocytes and tissue macrophages in respect to innate immune function of the cells in
      patients with cirrhosis at different stages of disease (Child A, B, C, acute decompensation,
      acute-on-chronic liver failure (ACLF)) and in comparison to patients with acute liver failure
      and to healthy controls.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in MERTK signalling cascade on monocytes</measure>
    <time_frame>days 1 (Baseline), 3, 7, and 14; then followed 6-monthly for up to 36 months</time_frame>
    <description>Change in MERTK signalling cascade on monocytes in respect to innate immune function of the cells in patients with cirrhosis at different stages of disease (Child A, B, C, acute decompensation, ACLF) and in comparison to patients with acute liver failure and to healthy controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in MERTK signalling cascade on tissue macrophages</measure>
    <time_frame>days 1 (Baseline), 3, 7, and 14; then followed 6-monthly for up to 36 months</time_frame>
    <description>Change in MERTK signalling cascade on tissue macrophages in respect to innate immune function of the cells in patients with cirrhosis at different stages of disease (Child A, B, C, acute decompensation, ACLF) and in comparison to patients with acute liver failure and to healthy controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mechanism of MERTK activation in cell culture models using monocytes</measure>
    <time_frame>days 1 (Baseline), 3, 7, and 14; then followed 6-monthly for up to 36 months</time_frame>
    <description>Change in mechanism of MERTK activation in cell culture models using healthy and diseased monocytes in vitro and ex vivo</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Liver Disease</condition>
  <condition>Cirrhosis of the Liver</condition>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <condition>Liver Failure</condition>
  <arm_group>
    <arm_group_label>cirrhosis of the liver, stadium Child A</arm_group_label>
    <description>sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cirrhosis of the liver, stadium Child B</arm_group_label>
    <description>sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cirrhosis of the liver, stadium Child C</arm_group_label>
    <description>sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cirrhosis of the liver, acutely decompensated</arm_group_label>
    <description>sampling of biological material and health related data collection on days 1 (Baseline), 3, 7, and 14. If acutely decompensated patients re-compensate they will be followed 6-monthly for up to 36 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acute liver failure</arm_group_label>
    <description>sampling of biological material and health related data collection on days 1 (Baseline), 3, 7, and 14. If acutely decompensated patients re-compensate they will be followed 6-monthly for up to 36 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <description>sampling of biological material and health related data collection on day 1 (Baseline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampling for research purpose</intervention_name>
    <description>blood sampling for research purpose (about 30ml) taken by venepuncture or from intravenous catheters if already in place</description>
    <arm_group_label>acute liver failure</arm_group_label>
    <arm_group_label>cirrhosis of the liver, acutely decompensated</arm_group_label>
    <arm_group_label>cirrhosis of the liver, stadium Child A</arm_group_label>
    <arm_group_label>cirrhosis of the liver, stadium Child B</arm_group_label>
    <arm_group_label>cirrhosis of the liver, stadium Child C</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clinical data collection</intervention_name>
    <description>clinical data collection in order to document the stage of disease, the presence of infection and existing complications of cirrhosis (ascites, hepatic encephalopathy, renal dysfunction, pulmonary dysfunction) and concomitant disease. These data will be collected for clinical reasons as highly important in the context of patients with cirrhosis and possible decompensation or liver failure and will therefore not require additional time</description>
    <arm_group_label>acute liver failure</arm_group_label>
    <arm_group_label>cirrhosis of the liver, acutely decompensated</arm_group_label>
    <arm_group_label>cirrhosis of the liver, stadium Child A</arm_group_label>
    <arm_group_label>cirrhosis of the liver, stadium Child B</arm_group_label>
    <arm_group_label>cirrhosis of the liver, stadium Child C</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Health-related Questionnaires</intervention_name>
    <description>Health-related Questionnaires (Questionnaire_CLD) regarding sleep characteristics (Pittsburgh sleep Quality index, PSQI), daytime sleepiness (Epworth sleepiness scale, ESS), anxiety and depression (Hospital Anxiety and Depression Scale, HADS) and quality of life (EQ-5D-5L)</description>
    <arm_group_label>acute liver failure</arm_group_label>
    <arm_group_label>cirrhosis of the liver, acutely decompensated</arm_group_label>
    <arm_group_label>cirrhosis of the liver, stadium Child A</arm_group_label>
    <arm_group_label>cirrhosis of the liver, stadium Child B</arm_group_label>
    <arm_group_label>cirrhosis of the liver, stadium Child C</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)</intervention_name>
    <description>Other biological material (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies) will only be investigated if sampled for clinical reasons and if excessive material is available that is not needed for clinical purpose.</description>
    <arm_group_label>acute liver failure</arm_group_label>
    <arm_group_label>cirrhosis of the liver, acutely decompensated</arm_group_label>
    <arm_group_label>cirrhosis of the liver, stadium Child A</arm_group_label>
    <arm_group_label>cirrhosis of the liver, stadium Child B</arm_group_label>
    <arm_group_label>cirrhosis of the liver, stadium Child C</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biological material will be stored in -80°C and -140°C freezers at the sites of recruitment.

      If biological material (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)
      are sampled routinely for clinical reasons and exceeding material allows additional
      scientific investigations, a small amount of the material will be used. The samples will be
      destroyed 10 years after publication of the study
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Prospective recruitment of patients with cirrhosis, acute decompensation, acute liver
        failure as pathological controls and healthy controls or controls with no liver disease at
        the Cantonal Hospital St. Gallen (KSSG), University Hospital Basel, St. Mary's Hospital,
        Imperial College London and King's College Hospital, London, UK.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with compensated or decompensated chronic liver disease

          -  Patients with acute- or acute-on-chronic chronic liver failure

          -  Controls with no liver disease

        Exclusion Criteria:

          -  Evidence of disseminated malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Bernsmeier, PD Dr. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsspital Basel, Departement Biomedizin, Gastroenterologie und Hepatologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Bernsmeier, PD Dr. Dr.</last_name>
    <phone>+41 61 77 77575</phone>
    <email>C.Bernsmeier@unibas.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Markus Heim, Prof. Dr. MD</last_name>
    <phone>+41 61 77 77490</phone>
    <email>markus.heim@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel, Hepatology Department and Laboratory</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Heim, Prof. Dr. MD</last_name>
      <phone>+41 61 265 55 19</phone>
      <email>markus.heim@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Bernsmeier, PD Dr. Dr.</last_name>
      <phone>+41 71 494 11 11</phone>
      <email>Christine.Bernsmeier@kssg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital, Institute of Liver studies</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia A Wendon, Prof.</last_name>
      <phone>+44 20 3299 3367</phone>
      <email>Julia.wendon@kcl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital, Imperial College London, Section of Hepatology</name>
      <address>
        <city>London</city>
        <zip>W2 1PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charalambos G Antoniades, Dr. med</last_name>
      <phone>+44 20 331 21903</phone>
      <email>c.antoniades@imperial.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 3, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunoparesis</keyword>
  <keyword>monocyte dysfunction</keyword>
  <keyword>MER receptor tyrosine kinase (MERTK)</keyword>
  <keyword>innate immune dysfunction</keyword>
  <keyword>circulating monocytes/macrophages</keyword>
  <keyword>MERTK signalling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

